Cardiac Cell-State Networks in Heart Failure: Mechanisms, Clinical Significance, and Emerging Therapeutic Insights

Abstract

Heart failure (HF) is a multifactorial syndrome with rising incidence and significant morbidity and mortality. Recent advances in single-cell and spatial transcriptomics have unveiled the complex landscape of cardiac cell-state networks that underlie the pathogenesis and progression of heart failure. This review synthesizes current evidence on the diverse cell states and their intercellular communication within the failing myocardium, highlights key mechanisms, clinical implications, and discusses recent advances in targeted therapies as well as guideline recommendations. An integrated understanding of cardiac cell-state networks provides novel opportunities for precision medicine in heart failure management.

Introduction

Heart failure remains a leading cause of hospitalization and mortality worldwide, representing a major clinical and public health challenge. Traditional models have focused on cardiomyocyte dysfunction; however, recent breakthroughs in single-cell omics and systems biology have demonstrated that heart failure is orchestrated by intricate networks of diverse cardiac cell populations. These cell states—encompassing cardiomyocytes, fibroblasts, endothelial cells, immune cells, and others—undergo dynamic phenotypic changes and interact in complex ways that drive disease progression. Understanding these cellular networks is essential for unraveling the mechanisms of heart failure and developing novel therapeutic strategies.

Epidemiology / Disease Burden

Globally, heart failure affects over 64 million individuals and is associated with substantial healthcare costs, frequent hospitalizations, and diminished quality of life. The prevalence increases with age, impacting 1-2% of adults in developed countries and up to 10% of those aged over 70 years. Despite advances in therapy, the five-year mortality rate remains high, approaching 50%. The growing burden underscores the urgent need for improved mechanistic understanding and targeted interventions.

Pathophysiology

The pathophysiology of heart failure extends beyond cardiomyocyte contractile dysfunction. Modern studies using single-nucleus RNA sequencing and spatial omics have revealed that cardiac remodeling involves dynamic alterations across multiple cell types. Cardiomyocytes exhibit diverse stress-responsive states, including hypertrophy, metabolic reprogramming, and apoptosis. Cardiac fibroblasts transition into activated myofibroblasts with enhanced extracellular matrix deposition, leading to fibrosis and increased myocardial stiffness. Endothelial cells assume pro-inflammatory and pro-thrombotic phenotypes, compromising vascular integrity. Resident and infiltrating immune cells, such as macrophages and T cells, contribute to maladaptive inflammation and tissue remodeling. Crosstalk via paracrine signaling, extracellular vesicles, and direct cell-cell contact orchestrates these processes, forming a cell-state network that perpetuates heart failure.

Risk Factors

Major risk factors for heart failure include ischemic heart disease, hypertension, diabetes mellitus, obesity, valvular heart disease, and genetic predisposition. Non-cardiac factors, such as chronic kidney disease and inflammatory conditions, also contribute. Chronic exposure to these risk factors induces persistent cellular stress, triggering maladaptive cell-state transitions, including myocyte loss, fibroblast activation, and immune cell infiltration, thereby accelerating the progression to overt heart failure.

Clinical Features

Heart failure manifests with a constellation of symptoms and signs, including exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, fatigue, reduced exercise tolerance, peripheral edema, jugular venous distension, and pulmonary rales. The clinical phenotype is shaped by the underlying cellular alterations, with fibrosis leading to diastolic dysfunction and immune activation contributing to cachexia and arrhythmias. Biomarker discovery, driven by cell-state profiling, is refining phenotypic classification and risk stratification.

Diagnosis

Accurate diagnosis of heart failure relies on a combination of clinical assessment, imaging, and laboratory biomarkers. Echocardiography remains the cornerstone, providing insights into ejection fraction, chamber size, wall thickness, and valvular function. Cardiac MRI offers superior tissue characterization, detecting fibrosis and inflammation. Circulating biomarkers such as natriuretic peptides (BNP, NT-proBNP) reflect cardiac stress and have prognostic value. Emerging biomarkers, including extracellular vesicle cargo and cell-state specific transcripts, are under investigation for early detection and monitoring.

Treatment & Management

Contemporary management of heart failure involves a combination of lifestyle modification, pharmacotherapy, device therapy, and, in selected cases, advanced interventions such as transplantation. Guideline-directed medical therapy includes beta-blockers, renin-angiotensin system inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors, all of which modulate cellular pathways implicated in maladaptive remodeling. Device-based therapies, such as implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT), address arrhythmogenic remodeling and electrical dyssynchrony. Multidisciplinary care, including management of comorbidities and patient education, is essential.

Recent Advances / Emerging Therapies

Recent advances have focused on targeting specific cell-state transitions and intercellular communication in heart failure. Fibroblast-specific inhibitors (e.g., anti-fibrotic agents), immune-modulatory therapies (e.g., anti-inflammatory biologics), and regenerative strategies (e.g., stem cell or extracellular vesicle therapy) are being evaluated in clinical trials. Single-cell transcriptomic profiling is enabling precision medicine approaches, matching patients to therapies based on cellular signatures. Novel drugs that modulate paracrine signaling or epigenetic regulators of cell fate hold promise for reversing maladaptive remodeling. The integration of multi-omics with clinical phenotyping is accelerating the identification of new therapeutic targets.

Guideline Recommendations

Current guidelines from the American College of Cardiology (ACC), American Heart Association (AHA), and European Society of Cardiology (ESC) emphasize early diagnosis, risk stratification, and implementation of evidence-based therapies. While guidelines currently focus on clinical and biomarker phenotypes, emerging recommendations recognize the potential of cell-state network profiling for individualized patient management. Ongoing research is expected to translate these insights into actionable guideline updates in the near future.

Conclusion

An in-depth understanding of cardiac cell-state networks has transformed our approach to the pathogenesis and management of heart failure. Integrating single-cell insights with clinical practice offers the potential for precision medicine, improved therapeutic targeting, and better patient outcomes. Continued research into the dynamic interplay of cardiac cell states will drive future innovations and guideline evolution, ultimately reducing the burden of heart failure worldwide.